The Economist @TheEconomist
“They’re licensing the drug very generously around the world.” @natashaloder, The Economist’s health-policy editor, explains how Merck’s molnupiravir antiviral for covid-19 is a breakthrough. Listen to “Babbage” https://t.co/ggMqIhX0S2 — PolitiTweet.org